Key statistics
52-week range
| Open | 2.13 |
|---|---|
| High | 2.18 |
| Low | 2.00 |
| Bid | 2.00 |
| Offer | 2.19 |
| Previous close | 2.12 |
| Average volume | 50.47k |
|---|---|
| Shares outstanding | 1.43k |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | 15.18m USD |
| EPS (TTM) | -7,200.04 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
- NuCana Appoints Theresa Bruce as Chief Operating Officer
- NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
- NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
- NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
- NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
- NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
- NuCana Compliant with All Nasdaq Continued Listing Criteria
- NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
- NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
- NuCana Announces ADS Ratio Change
More ▼
